At Aetion, Maya leads development and sales of new products that leverage the Aetion Evidence Platform for real-world evidence (RWE) generation. A particular focus is supporting US payer and pharma clients on innovative drug contracting and other applications of RWE. Prior to joining Aetion, Maya was a Principal in BCG’s healthcare practice, where she worked with US payers on strategic and operational topics across Commercial and Medicare, as well as with Pharma manufacturers’ Commercial and Market Access teams. Maya holds an MBA from Wharton and a BA from Harvard.
Financing Transformative Therapies: Cross-sector perspective on value, payment and real-world evidence
Value based contracting approaches, which need to be informed by real-world evidence, become…